Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases
Michael Kasperkiewicz(University of California, Los Angeles), Enno Schmidt(Carrier (United States)), Nicolas Hunzelmann(University Hospital Cologne), Klaus Freivogel, Hendrik Schulze‐Koops(LMU Klinikum), Thomas Dörner(German Rheumatism Research Centre), Detlef Zillikens(University of Lübeck), Michael Meurer(University Hospital Carl Gustav Carus), Melika Behzad(Philipps University of Marburg), Rüdiger Eming(Philipps University of Marburg), Peter von Wussow, Michael Hertl(Universitätsklinikum Gießen und Marburg)
JDDG Journal der Deutschen Dermatologischen Gesellschaft
May 11, 2012
Cited by 49
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus
|Journal of the American Academy of Dermatology|2008|597
Guidelines for the use of flow cytometry and cell sorting in immunological studies <sup>*</sup>
|European Journal of Immunology|2017|554
Diagnosis and management of pemphigus: Recommendations of an international panel of experts
|Journal of the American Academy of Dermatology|2018|384